Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
482.04M | 433.14M | 450.89M | 468.06M | 338.30M | Gross Profit |
366.30M | 326.66M | 345.87M | 353.86M | 250.98M | EBIT |
-1.28M | 12.53M | 22.30M | 72.92M | 27.41M | EBITDA |
-1.28M | 36.03M | 40.32M | 87.00M | 37.23M | Net Income Common Stockholders |
861.00K | 4.95M | 15.53M | 94.20M | 17.23M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
135.57M | 104.34M | 102.48M | 113.93M | 84.39M | Total Assets |
497.89M | 460.02M | 449.36M | 443.26M | 294.49M | Total Debt |
43.31M | 119.35M | 123.79M | 132.30M | 84.77M | Net Debt |
-92.26M | 15.51M | 21.31M | 18.37M | 377.00K | Total Liabilities |
112.57M | 181.36M | 183.69M | 201.22M | 148.41M | Stockholders Equity |
262.90M | 278.66M | 265.67M | 242.03M | 146.08M |
Cash Flow | Free Cash Flow | |||
4.18M | 6.55M | -9.04M | 30.76M | -14.34M | Operating Cash Flow |
14.21M | 30.92M | 24.86M | 61.98M | 6.80M | Investing Cash Flow |
-10.03M | -24.36M | -33.90M | -31.22M | -24.83M | Financing Cash Flow |
27.64M | -5.50M | -2.20M | -1.04M | 42.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $3.93B | 34.83 | 7.71% | ― | 8.49% | 31.15% | |
68 Neutral | $570.73M | 803.57 | 0.26% | ― | 11.29% | -79.52% | |
67 Neutral | $1.11B | 26.50 | 25.01% | ― | 8.52% | -32.91% | |
55 Neutral | $230.10M | ― | -230.96% | ― | 32.24% | -66.93% | |
52 Neutral | $256.56M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 19.94% | 1.20% | |
43 Neutral | $439.60M | ― | -12.32% | ― | -9.23% | -359.07% |
On March 27, 2025, Organogenesis Holdings Inc. released an investor presentation highlighting its strategic focus on addressing large unmet patient needs in chronic and acute wounds and osteoarthritis. The presentation outlines the company’s market opportunities and technological advancements, emphasizing its commitment to leading innovation in regenerative therapies. The company faces challenges such as competition and regulatory changes, but it continues to focus on enhancing its product offerings to maintain its competitive edge.